Eli Lilly and Co., of Indianapolis, said the European Commission granted marketing authorization for Trulicity (dulaglutide) solution for injection. Trulicity, a GLP-1 receptor agonist, is a once-weekly, injectable solution designed to improve glycemic control in adults with type 2 diabetes.